A Trial of Grazax in Subjects With Hayfever

This study has been completed.
Information provided by:
ALK-Abelló A/S
ClinicalTrials.gov Identifier:
First received: January 11, 2007
Last updated: June 23, 2015
Last verified: June 2015
The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.

Condition Intervention Phase
Drug: Grazax
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma

Resource links provided by NLM:

Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:
  • Recording of allergy symptoms [ Time Frame: Grass pollen season 2007 ] [ Designated as safety issue: Yes ]

Enrollment: 329
Study Start Date: December 2006
Study Completion Date: October 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Grazax
Tablets 75,000 SQT and matching placebo. One tablet daily.
Placebo Comparator: 2 Drug: Grazax
Tablets 75,000 SQT and matching placebo. One tablet daily.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of grass pollen allergy
  • Positive skin prick test to grass
  • Positive specific IgE to grass

Exclusion Criteria

  • FEV1 <70% of predicted value
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00421655

United States, Iowa
CompleWare Corporation
Iowa City, Iowa, United States, 52244-3090
Sponsors and Collaborators
ALK-Abelló A/S
Study Director: Kim Simonsen, MD ALK-Abelló A/S
  More Information

No publications provided by ALK-Abelló A/S

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kim Simonsen, MD, Senior Director, ALK-Abello
ClinicalTrials.gov Identifier: NCT00421655     History of Changes
Other Study ID Numbers: GT-14
Study First Received: January 11, 2007
Last Updated: June 23, 2015
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on November 27, 2015